Impact of COVID-19 on clinical trials protocol amendments
DOI:
https://doi.org/10.18413/rrpharmacology.9.10021Abstract
Introduction: The COVID-19 pandemic situation had a great impact on all spheres of people’s lives. It also affected clinical trials as Sponsors, sites and investigators faced a number of problems, such as systematic IMP taking, adherence to protocol visits, efficacy evaluations, laboratory procedures, and analyses.
Materials and Methods: The amendments issued in 2020 were compared with the amendments issued in the previous three years 2017-2019. The literature about COVID-19 and its impact on clinical trials were analyzed. Clinical trial protocol amendments published in 2020 were studied to evaluate pandemic influence on ongoing clinical studies. Statistical processing of the results was carried out using the correlation analysis.
Results: The highest quantity of amendments was released in 2020 –14 (36%). Fewer amendments came out in 2019 – 13 (33%), in 2018 – 9 (23%), and the fewest amendments were issued in 2017 – 3 (8%).
Conclusion: The existing system of clinical trial protocol creation is dependable and adequate. It allows reacting flexibly to unexpected challenges, like COVID-19, fully complying with the prescribed procedures and carefully observing participants’ safety and well-being. That is why the current pandemic did not affect the number of protocol amendments.
Graphical Abstract
Keywords:
COVID-19, clinical trials, pandemic 2020, protocol amendmentsReferences
Akacha M, Branson J, Bretz F, Dharan B, Gallo P, Gathmann I, Hemmings R, Jones J, Xi D, Zuber E (2020) Challenges in assessing the impact of the COVID-19 pandemic on the integrity and interpretability of clinical trials. Statistics in Biopharmaceutical Research 12(4): 419–426. https://doi.org/10.1080/19466315.2020.17889842[PubMed] [PMC]
AOKI (Russia) (2021) Information and Analytical Bulletin No. 22. Moscow, 60 pp.http://acto-russia.org/files/bulletin_22.pdf
Asaad M, Habibullah NK, Butler CE (2020) The impact of COVID-19 on clinical trials. Annals of Surgery 272: e222. https://doi.org/10.1097/SLA.0000000000004113
Beane JD, Dedhia PH, Ejaz A, Contreras CM, Cloyd JM, Tsung A, Pawlik TM (2020) Conducting clinical trials in the time of a pandemic. Annals of Surgery 272(3): e219–e221. https://doi.org/10.1097/SLA.0000000000004114 [PubMed] [PMC]
Chow SC, Jun S. Inference for clinical trials with some protocol amendments. Journal of Biopharmaceutical Statistics 15(4): 659–666. https://doi.org/10.1081/BIP-200062286 [PubMed]
Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI (2008) Assessing the impact of protocol design changes on clinical trial performance. American Journal of Therapeutics 15(5): 450–457. https://doi.org/10.1097/MJT.0b013e31816b9027 [PubMed]
Getz KA, Zuckerman R, Cropp AB (2011) Measuring the incidence, causes, and repercussions of protocol amendments. Drug Information Journal 45: 265–275. https://doi.org/10.1177/009286151104500307
Hasford J (2020) Impact of the COVID-19 pandemic on clinical trials with drugs. Expert Opinion on Drug Safety 19(11): 1373–1375. https://doi.org/10.1080/14740338.2020.1828861 [PubMed]
Kunz CU, Jörgens S, Bretz F, Stallard N, Van Lancker K, Xi D, Zohar S, Gerlinger C, Friede T (2020) Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue? Statistics in Biopharmaceutical Research 12(4): 461–477. https://doi.org/10.1080/19466315.2020.1799857 [PubMed] [PMC]
Ledford H (2020) Coronavirus shuts down trials of drugs for multiple other diseases. Nature 580(7801): 15–17. https://doi.org/10.1038/d41586-020-00889-6 [PubMed]
Meyer RD, Ratitch B, Wolbers M, Marchenko O, Quan H, Li D, Fletcher C, Li X, Wright D, Shentu Y, Englert S, Shen W, Dey J, Liu T, Zhou M, Bohidar N, Zhao PL, Hale M (2020) Statistical issues and recommendations for clinical trials conducted during the COVID-19 pandemic. Statistics in Biopharmaceutical Research 12(4): 399–411. https://doi.org/10.1080/19466315.2020.1779122 [PubMed] [PMC]
Moore TJ, Zhang H, Anderson G, Alexander GC (2018) Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Internal Medicine 178(11): 1451–1457. https://doi.org/10.1001/jamainternmed.2018.3931 [PubMed] [PMC]
Sathian B, Asim M, Banerjee I, Pizarro AB, Roy B, van Teijlingen ER, do Nascimento IJB, Alhamad HK (2020) Impact of COVID-19 on clinical trials and clinical research: A systematic review. Nepal Journal of Epidemiology 10(3): 878–887. https://doi.org/10.3126/nje.v10i3.31622 [PubMed] [PMC]
Singh AG, Pankaj C (2020) Clinical trials during COVID-19. Head & Neck 42(7): 1516–1518. https://doi.org/10.1002/hed.26223 [PubMed] [PMC]
Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM (2020) Impact of COVID-19 on oncology clinical trials. Nature Reviews. Drug Discovery 19(6): 376–377. https://doi.org/10.1038/d41573-020-00093-1 [PubMed]
Vissers MFJM, Cohen AF, Van Gerven JMA, Groeneveld GJ (2021) The impact of the global COVID‐19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis. British Journal of Clinical Pharmacology 87(3): 837–844. https://doi.org/10.1080/19466315.2020.1788984 [PubMed]
Русский
English
